ArticleJournal of neuro-oncology2026
Regret concerning treatment decisions in patients with primary or secondary brain tumors - a cross-sectional exploratory bicentric analysis.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the extent of decisional regret (DR) and contributing factors after treatment of primary and secondary brain tumors (BT).
methodsPatients who received radiotherapy (RT) for a BT between 2010 and 2024 were eligible for this bicentric cross-sectional study. DR was assessed using the 5-item Decision Regret Scale (DRS). Overall and treatment-specific DR was determined. Besides DR, health related quality of life (HRQoL), distress, anxiety, depression, and satisfaction with medical care were determined. Associations between DR and covariates were examined in univariate analyses. Linear regression models were calculated for multivariable analyses.
resultsFrom 310 eligible contacted patients, 162 were included. Ninety-four patients (58%) suffered from malignant glioma, and 68 (42%) had brain metastases (BM). Median age was 58 years, median interval between the last RT fraction and study participation 22 months. Thirty-two patients (20%) reported no, 85 (53%) mild, and 45 (28%) strong overall DR. Regarding their decision towards specific treatments, 37 patients (23%) expressed strong DR concerning RT, 45 (30%) regarding chemotherapy, and 29 patients (20%) with regard to brain surgery. Global HRQoL was inversely correlated to DR (r = -0.35, p < 0.001). Physical functioning (r = -0.33, p < 0.001) and social functioning (r = -0.32, p < 0.001) demonstrated moderate correlation. As symptoms, fatigue (r = 0.32, p < 0.001), future uncertainty (r = 0.37, p < 0.001), motor dysfunction (r = 0.32, p < 0.001), depression (r = 0.37, p < 0.001) and satisfaction with medical care (r = -0.39, p < 0.001) showed strong correlations with DR. In multivariable linear regression, low satisfaction with medical care, unemployment, future uncertainty and BM stayed associated with DR.
conclusionsDR is frequent in patients with BT. Rather than treatment-related, low satisfaction with medical care and unemployment/financial uncertainty appear particularly linked to higher DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.